OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, News, & Analysis

$13.51
0.00 (0.00 %)
(As of 06/24/2019 04:00 PM ET)
Today's Range
$13.47
Now: $13.51
$13.55
50-Day Range
$12.98
MA: $13.57
$13.97
52-Week Range
$12.41
Now: $13.51
$17.99
Volume114,099 shs
Average Volume93,937 shs
Market Capitalization$26.75 billion
P/E Ratio13.79
Dividend Yield1.26%
Beta0.7
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.00 billion
Cash Flow$1.0305 per share
Book Value$5.78 per share

Profitability

Net Income$1.55 billion

Miscellaneous

Employees16,617
Outstanding Shares1,980,000,000
Market Cap$26.75 billion
Next Earnings Date6/26/2019 (Estimated)
OptionableNot Optionable

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions

What is ASTELLAS PHARMA/ADR's stock symbol?

ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY."

When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work?

ASTELLAS PHARMA/ADR's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were issued to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split.

How were ASTELLAS PHARMA/ADR's earnings last quarter?

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) announced its quarterly earnings results on Wednesday, April, 25th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.15 by $0.05. The company had revenue of $2.78 billion for the quarter. ASTELLAS PHARMA/ADR had a return on equity of 16.46% and a net margin of 16.27%. View ASTELLAS PHARMA/ADR's Earnings History.

When is ASTELLAS PHARMA/ADR's next earnings date?

ASTELLAS PHARMA/ADR is scheduled to release their next quarterly earnings announcement on Wednesday, June 26th 2019. View Earnings Estimates for ASTELLAS PHARMA/ADR.

What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ASTELLAS PHARMA/ADR.

Has ASTELLAS PHARMA/ADR been receiving favorable news coverage?

Press coverage about ALPMY stock has been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ASTELLAS PHARMA/ADR earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the company's share price in the next several days. View News Stories for ASTELLAS PHARMA/ADR.

Who are some of ASTELLAS PHARMA/ADR's key competitors?

What other stocks do shareholders of ASTELLAS PHARMA/ADR own?

Who are ASTELLAS PHARMA/ADR's key executives?

ASTELLAS PHARMA/ADR's management team includes the folowing people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 59)
  • Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Linda Friedman, Gen. Counsel & VP
  • Dr. Sef P. Kurstjens, Chief Medical Officer and Pres of Global Devel. (Age 56)

How do I buy shares of ASTELLAS PHARMA/ADR?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ASTELLAS PHARMA/ADR's stock price today?

One share of ALPMY stock can currently be purchased for approximately $13.51.

How big of a company is ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR has a market capitalization of $26.75 billion and generates $12.00 billion in revenue each year. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe.View Additional Information About ASTELLAS PHARMA/ADR.

What is ASTELLAS PHARMA/ADR's official website?

The official website for ASTELLAS PHARMA/ADR is http://www.astellas.com/.

How can I contact ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.


MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel